News
A Financial District-based drug discovery company inked a $1 billion licensing agreement with pharmaceutical giant AbbVie to develop its signature cancer drug. IGI Therapeutics SA, a subsidiary of the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback